Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx Primer Ai Platform

The Company's next-generation diagnostics technology, enhanced by proprietary AI models, enables real-time PCR diagnostics at the point-of-care

Co-Diagnostics, a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence (AI) business unit, led by Chief Technology & AI Officer Christopher Thurston, to integrate the Company's existing and planned AI applications into the Co-Dx™ Primer Ai™ platform.

Co-Dx anticipates that allocating resources to the newly formed AI business unit will enable the Company to develop proprietary AI-powered diagnostics more efficiently and reduce time-to-market for new tests. The Company also believes that future AI tools will be able to leverage the analytics yielded from widespread deployment and commercialisation of the Co-Dx PCR Pro* to improve situational awareness during a health crisis, and potentially predict outbreaks and pandemics before they occur.

"Since our founding in 2013, Co-Diagnostics has been at the forefront of PCR technology innovation, beginning with the introduction of the revolutionary Co-Primers® technology, and later with the development of the Co-Dx PCR platform to help close the diagnostics access gap," remarked Dwight Egan, Co-Dx Chief Executive Officer. "Now, as the rate of adoption of enterprise artificial intelligence increases and AI applications continue to grow in ubiquity and utility, we have begun incorporating these next-generation tools to help increase operational efficiency, minimise human error, improve outcomes in real-time point-of-care testing, and truly give physicians, patients, and communities the Power to Know™."

The Company's next-generation diagnostics technology, enhanced by proprietary AI models, enables real-time PCR diagnostics at the point-of-care. Co-Dx's AI models support internal data and workflow orchestration, as well as Co-Primers design and optimisation. Future models will enhance automated test interpretation and create predictive epidemiological awareness. These models will operate in tandem with the Company's HIPAA-compliant Co-Dx cloud platform and internal databases to form the foundation of Co-Dx Primer Ai.